Fidia Farmaceutici, S.p.A. Presents New Data On Hymovis, A Breakthrough In Viscoelastic Technology, At The American Orthopaedic Society For Sports Medicine 2016 Annual Meeting

PARSIPPANY, N.J.--(BUSINESS WIRE)--Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia Pharma USA Inc., will feature Hymovis® (high molecular weight viscoelastic hyaluronan), which is now commercially available in the U.S., at the Annual Meeting of the American Orthopaedic Society for Sports Medicine (AOSSM) in Colorado Springs, Colorado, July 7-10, 2016.

MORE ON THIS TOPIC